Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-09-04
|
DAV131 |
Clostridium difficile infection |
preclinical |
Da Volterra (France) |
Infectious diseases |
2017-08-31
|
mirogabalin (DS-5565) |
diabetic peripheral neuropathic pain - postherpetic neuralgia |
3 |
Daiichi Sankyo (Japan) |
CNS diseases - Neurological diseases |
2017-08-30
|
MP0250 |
solid tumors |
1 |
Molecular Partners (Switzerland) |
Cancer - Oncology |
2017-08-30
|
MP0250 and osimertinib (Tagrisso®) |
|
1b/2 |
Molecular Partners (Switzerland) |
Cancer - Oncology |
2017-08-29
|
PBD-C06 |
Alzheimer's disease |
preclinical |
Probiodrug (Germany) |
Neurodegenerative diseases |
2017-08-29
|
DS-8201 |
HER2-positive unresectable and/or metastatic breast cancer resistant or refractory to ado-trastuzumab emtansine (T-DM1) |
2 |
Daiichi Sankyo (Japan) |
Cancer - Oncology |
2017-08-28
|
imeglimin |
type 2 diabetes |
preclinical |
Poxel (France) |
Metabolic diseases |
2017-08-28
|
inclisiran (ALN-PCSsc) |
atherosclerotic cardiovascular disease, familial hypercholesterolemia |
2 |
Alnylam Therapeutics (USA - MA) The Medicines Company (USA - NJ) |
Cardiovascular diseases - Genetic diseases |
2017-08-28
|
nivolumab and DS-8201 |
HER2-expressing metastatic breast cancer, HER2-expressing metastatic urothelial cancer |
1b |
BMS (USA - NY) Daiichi Sankyo (Japan) |
Cancer - Oncology |
2017-08-24
|
daratumumab in combination with bortezomib, melphalan and prednisone |
front line multiple myeloma |
3 |
Janssen Biotech - J&J (USA) Genmab (Denmark) |
Cancer - Oncology |
2017-08-24
|
AAV2/8-hCARp.hCNGB3 - adenovirus associated viral vector serotype 8 containing the human CNGB3 gene |
achromatopsia due to mutations in the CNGB3 gene |
1-2 |
MeiraGTx (USA - NY) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-08-24
|
AAV2/5-hRKp.RPGR |
X-Linked retinitis pigmentosa (XLRP) |
1-2 |
MeiraGTx (USA - NY) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-08-24
|
BI 1467335 (formerly known as PXS-4728A) |
NASH (non-alcoholic steatohepatitis) |
2a |
Boehringer Ingelheim (Germany) Pharmaxis (Australia) |
Liver diseases - Hepatic diseases |
2017-08-22
|
antibodies against alpha-synuclein and TDP-43 |
neurodegenerative diseases |
preclinical |
AC Immune (Switzerland) |
Neurodegenerative diseases |
2017-08-22
|
PAT-1251 |
idiopathic pulmonary fibrosis (IPF), fibrotic diseases |
1 |
PharmAkea (USA - CA) |
Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases |
2017-08-21
|
KAF156 in combination with lumefantrine |
malaria |
2b |
Novartis (Switzerland) |
Parasitic diseases |
2017-08-21
|
TAK-935/OV935 |
developmental and/or epileptic encephalopathies, including Dravet Syndrome, Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex |
1b/2a |
Ovid Therapeutics (USA - NY) |
Neurological diseases - CNS diseases - Neurodevelopmental diseases |
2017-08-21
|
gilteritinib |
acute myeloid leukemia with FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) |
3 |
Astellas Pharma (Japan) |
Cancer - Oncology |
2017-08-17
|
KITE-718 (MAGE A3/A6 -Autologous genetically modified MAGE-A3/A6 TCR transduced T cells) |
solid tumors |
1 |
Kite Pharma (USA - CA) |
Cancer - Oncology |
2017-08-16
|
MIV-711 |
osteoarthritis |
2 |
Medivir (Sweden) |
Rheumatic diseases - Inflammatory diseases – Bone diseases |